Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Depreciation and Depletion: 2014-2024

Historic Depreciation and Depletion for Northwest Biotherapeutics (NWBO) over the last 8 years, with Jun 2024 value amounting to $500,000.

  • Northwest Biotherapeutics' Depreciation and Depletion rose 25.00% to $500,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $1.7 million, marking a year-over-year increase of 21.43%. This contributed to the annual value of $1.7 million for FY2024, which is 13.33% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Depreciation and Depletion of $500,000 as of Q2 2024, which was up 25.00% from $400,000 recorded in Q1 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Depreciation and Depletion peaked at $500,000 during Q2 2022, and registered a low of $14,000 during Q2 2020.
  • Its 3-year average for Depreciation and Depletion is $370,000, with a median of $400,000 in 2024.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Depreciation and Depletion spiked by 980.00% in 2020, and later declined by 20.00% in 2023.
  • Northwest Biotherapeutics' Depreciation and Depletion (Quarterly) stood at $54,000 in 2020, then reached $400,000 in 2022, then remained steady at $400,000 in 2023, then increased by 25.00% to $500,000 in 2024.
  • Its Depreciation and Depletion was $500,000 in Q2 2024, compared to $400,000 in Q1 2024 and $400,000 in Q4 2023.